Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc. - Common Shares
(NQ:
XENE
)
44.49
-0.33 (-0.74%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xenon Pharmaceuticals Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
Next >
Xenon Pharmaceuticals Earnings Perspective: Return On Capital Employed
↗
December 06, 2022
Via
Benzinga
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
December 02, 2022
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022
November 30, 2022
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
↗
November 29, 2022
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.
Via
Investor's Business Daily
Where Xenon Pharmaceuticals Stands With Analysts
↗
November 28, 2022
Via
Benzinga
Analyst Sees This Epilepsy Player As 'M&A Sweet Spot'
↗
October 19, 2022
Via
Benzinga
4 Analysts Have This to Say About Xenon Pharmaceuticals
↗
October 11, 2022
Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings:
Via
Benzinga
Analyst Ratings for Xenon Pharmaceuticals
↗
August 29, 2022
Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 28, 2022
↗
November 28, 2022
Via
Benzinga
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
November 09, 2022
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
↗
November 09, 2022
Biotech stocks were hammered Wednesday, including several that had good news.
Via
Investor's Business Daily
4 Analysts Have This to Say About Xenon Pharmaceuticals
↗
August 11, 2022
Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings:
Via
Benzinga
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Earnings Scheduled For November 8, 2022
↗
November 08, 2022
Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Via
Benzinga
Earnings Preview: Xenon Pharmaceuticals
↗
November 07, 2022
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Xenon...
Via
Benzinga
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary
November 07, 2022
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures
November 03, 2022
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends.
↗
November 01, 2022
As the Fed continues to tighten the market, consider putting these seven on your list of overvalued Nasdaq stocks to sell before 2022 ends.
Via
InvestorPlace
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update
November 01, 2022
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022
↗
October 19, 2022
Upgrades
Via
Benzinga
Swing Trading Stock Watchlist For The Week Of Sept. 6
↗
September 04, 2022
The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look.
Via
Talk Markets
Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says
↗
August 29, 2022
Xenon Pharmaceuticals Inc’s (NASDAQ: XENE) epilepsy candidate, XEN1101, is currently in phase III trials and “looks poised to be a blockbuster,” according to BofA Securities.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
↗
August 29, 2022
Upgrades
Via
Benzinga
What 4 Analyst Ratings Have To Say About Xenon Pharmaceuticals
↗
August 11, 2022
Analysts have provided the following ratings for Xenon Pharmaceuticals (NASDAQ:XENE) within the last quarter:
Via
Benzinga
Xenon Pharmaceuticals: Q2 Earnings Insights
↗
August 09, 2022
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For August 9, 2022
↗
August 09, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Via
Benzinga
Earnings Outlook For Xenon Pharmaceuticals
↗
August 08, 2022
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022
↗
July 21, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
↗
June 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Why Xenon Pharma Flirted With A Breakout — And Then Sacrificed It All
↗
June 23, 2022
The company had bullish results in seizure treatment. But it wasn't enough.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
